ALPHA METHYLACYL A COENZYME RACEMASE DETECTION

• US 20070287164A1
• Filed: 06/06/2007
• Published: 12/13/2007
• Est. Priority Date: 06/06/2006
• Status: Abandoned Application

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: Huang, Wei, Jarrard, David
• Application Number:
  US11/759,098
• Publication Number:
  US 20070287164A1
• Time in Patent Office: Days
• US Class Current: 435/7.230
• CPC Class Codes: G01N 2333/99 Isomerases (5.)
• CPC Class Codes: G01N 33/573 for enzymes or isoenzymes
• CPC Class Codes: G01N 33/57434 of prostate

Abstract

A method of detecting the presence or absence of alpha methylacyl A coenzyme racemase (AMACR) is provided. In one embodiment of the method, a fluid including a secretion chosen from at least one of a prostate secretion or a secretion from an accessory glad or a cellular component of the fluid is obtained from a subject. The fluid is contacted with a reagent for detecting AMACR under conditions such that the reagent detects AMACR in the semen. The level of AMACR is determined such as by comparing it to a standard curve. The fluid can be semen or a prostate secretion or another fluid. A kit that can be used with the method is also provided.

Claims

1. A method of detecting the presence or absence of alpha methylacyl A coenzyme racemase (AMACR), comprising:

a) obtaining a fluid including a secretion chosen from at least one of a prostate secretion or a secretion from an accessory glad or a cellular component of the fluid from a subject; and

b) contacting the fluid with a reagent for detecting AMACR under conditions such that the reagent detects AMACR in the fluid.

2. The method of claim 1, wherein the fluid comprises semen.

3. The method of claim 1, wherein the fluid comprises a prostate secretion.

4. The method of claim 1, wherein the level of AMACR in the fluid is determined.

5. The method of claim 4, wherein the level of AMACR in the fluid is determined by comparing it to a standard curve.

6. The method of claim 1, wherein the presence of AMACR in the fluid at a level above an age-appropriate minimum threshold level is indicative of a diagnosis of prostate cancer or a precancerous prostate condition in the subject.

7. The method of claim 1, wherein the reagent is an antibody.

8. The method of claim 7, wherein the antibody is capable of forming a complex with the AMACR, and further comprising determining the amount of complex formed as a measure of the presence or amount of AMACR in the semen, wherein the amount of complex determined is indicative of a diagnosis of prostate cancer, a precancerous condition, or a prognosis of prostate cancer in the subject.

9. The method of claim 8, wherein the amount of complex determined is indicative of a diagnosis of prostate cancer.

10. The method of claim 7, wherein the antibody comprises a label selected from the group consisting of an enzyme, a radioactive label, a fluorescent label, a fluorescence emitting metal, a chemiluminescent label, a chromophoric label, and a bioluminescent label.

11. A method for diagnosing prostate cancer or a precancerous prostate condition in a subject, comprising:

a) providing a sample including a secretion chosen from at least one of a prostate secretion or a secretion from an accessory gland or a cellular component of the fluid from the subject;

b) detecting a level of alpha methylacyl A coenzyme racemase (AMACR) in the sample; and

c) using the level of AMACR present in the sample to determine whether the subject has prostate cancer or a precancerous prostate condition.

12. The method of claim 11, wherein the sample comprises semen.

13. The method of claim 11, wherein the sample comprises a prostate secretion.

14. The method of claim 11, wherein the detecting level of AMACR comprises exposing the sample to a first antibody specific to AMACR and detecting binding of the antibody to AMACR.

15. The method of claim 14, wherein the detecting the level of AMACR further comprises providing a second antibody specific to AMACR.

16. The method of claim 15, wherein the detecting further comprises providing a third antibody, wherein at least one the second and third antibody includes a label.

17. The method of claim 16, wherein the label is selected from the group consisting of an enzyme, a radioactive label, a fluorescent label, a fluorescence emitting metal, a chemiluminescent label, a chromophoric label, and a bioluminescent label.

18. The method of claim 11, wherein the subject comprises a human subject.

19. A kit comprising:

a) a positive control that reacts with a reagent for detecting alpha methylacyl A coenzyme racemase (AMACR); and

b) a negative control that does not react with the reagent.

20. The kit of claim 19, further comprising a reagent capable of detecting AMACR.

21. The kit of claim 20, wherein the reagent comprises a first antibody that binds to AMACR.

22. The kit of claim 21, further comprising a second antibody that detects AMACR.

23. The kit of claim 22, further comprising a third antibody that binds to the second antibody.

24. The kit of claim 23, wherein at least one of the second antibody and the third antibody comprises a label.